Works by Hosoya, Kazutaka

Results: 19
    1

    Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.

    Published in:
    NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00350-7
    By:
    • Katayama, Yuki;
    • Yamada, Tadaaki;
    • Tanimura, Keiko;
    • Tokuda, Shinsaku;
    • Morimoto, Kenji;
    • Hirai, Soichi;
    • Matsui, Yohei;
    • Nakamura, Ryota;
    • Ishida, Masaki;
    • Kawachi, Hayato;
    • Yoneda, Kazue;
    • Hosoya, Kazutaka;
    • Tsuji, Takahiro;
    • Ozasa, Hiroaki;
    • Yoshimura, Akihiro;
    • Iwasaku, Masahiro;
    • Kim, Young Hak;
    • Horinaka, Mano;
    • Sakai, Toshiyuki;
    • Utsumi, Takahiro
    Publication type:
    Article
    2
    3

    Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

    Published in:
    2020
    By:
    • Hosoya, Kazutaka;
    • Fujimoto, Daichi;
    • Morimoto, Takeshi;
    • Kumagai, Toru;
    • Tamiya, Akihiro;
    • Taniguchi, Yoshihiko;
    • Yokoyama, Toshihide;
    • Ishida, Tadashi;
    • Hirano, Katsuya;
    • Matsumoto, Hirotaka;
    • Kominami, Ryota;
    • Tomii, Keisuke;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Kanazu, Masaki;
    • Sawa, Nobuhiko;
    • Makio, Takeshi;
    • Hara, Satoshi
    Publication type:
    journal article
    4
    5
    6
    7
    8

    Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

    Published in:
    Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-03139-5
    By:
    • Ajimizu, Hitomi;
    • Ozasa, Hiroaki;
    • Sato, Susumu;
    • Funazo, Tomoko;
    • Sakamori, Yuichi;
    • Nomizo, Takashi;
    • Kuninaga, Kiyomitsu;
    • Ogimoto, Tatsuya;
    • Hosoya, Kazutaka;
    • Yamazoe, Masatoshi;
    • Tsuji, Takahiro;
    • Yoshida, Hironori;
    • Itotani, Ryo;
    • Ueno, Kentaro;
    • Kim, Young Hak;
    • Muro, Shigeo;
    • Hirai, Toyohiro
    Publication type:
    Article
    9
    10
    11
    12

    Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients.

    Published in:
    BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12798-2
    By:
    • Hosoya, Kazutaka;
    • Ozasa, Hiroaki;
    • Tanji, Masahiro;
    • Yoshida, Hiroshi;
    • Ajimizu, Hitomi;
    • Tsuji, Takahiro;
    • Yoshida, Hironori;
    • Terada, Yukinori;
    • Sano, Noritaka;
    • Mineharu, Yohei;
    • Miyamoto, Susumu;
    • Hirai, Toyohiro;
    • Arakawa, Yoshiki
    Publication type:
    Article
    13

    Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 2, p. 361, doi. 10.1007/s10637-021-01203-5
    By:
    • Tamiya, Motohiro;
    • Fujikawa, Kei;
    • Suzuki, Hidekazu;
    • Yokoyama, Toshihide;
    • Uenami, Takeshi;
    • Tamiya, Akihiro;
    • Sato, Yuki;
    • Saito, Go;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Hirashima, Tomonori;
    • Fukuda, Yasushi;
    • Kanazu, Masaki;
    • Hosoya, Kazutaka;
    • Suzuki, Takuji;
    • Ueno, Kiyonobu;
    • Fujimoto, Daichi;
    • Kumagai, Toru;
    • Teramukai, Satoshi
    Publication type:
    Article
    14
    15
    16

    Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 1, p. 211, doi. 10.1007/s10637-019-00882-5
    By:
    • Kawachi, Hayato;
    • Tamiya, Motohiro;
    • Tamiya, Akihiro;
    • Ishii, Seigo;
    • Hirano, Katsuya;
    • Matsumoto, Hirotaka;
    • Fukuda, Yasushi;
    • Yokoyama, Toshihide;
    • Kominami, Ryota;
    • Fujimoto, Daichi;
    • Hosoya, Kazutaka;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Kanazu, Masaki;
    • Sawa, Nobuhiko;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Makio, Takeshi;
    • Hara, Satoshi;
    • Kumagai, Toru
    Publication type:
    Article
    17

    Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).

    Published in:
    Investigational New Drugs, 2019, v. 37, n. 6, p. 1266, doi. 10.1007/s10637-019-00843-y
    By:
    • Tamiya, Motohiro;
    • Tamiya, Akihiro;
    • Hosoya, Kazutaka;
    • Taniguchi, Yoshihiko;
    • Yokoyama, Toshihide;
    • Fukuda, Yasushi;
    • Hirano, Katsuya;
    • Matsumoto, Hirotaka;
    • Kominami, Ryota;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Kanazu, Masaki;
    • Sawa, Nobuhiko;
    • Kinoshita, Yoshinori;
    • Hara, Satoshi;
    • Kumagai, Toru;
    • Fujimoto, Daichi
    Publication type:
    Article
    18
    19

    Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.

    Published in:
    2021
    By:
    • Hosoya, Kazutaka;
    • Fujimoto, Daichi;
    • Morimoto, Takeshi;
    • Kumagai, Toru;
    • Tamiya, Akihiro;
    • Taniguchi, Yoshihiko;
    • Yokoyama, Toshihide;
    • Ishida, Tadashi;
    • Matsumoto, Hirotaka;
    • Hirano, Katsuya;
    • Kominami, Ryota;
    • Tomii, Keisuke;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Tanaka, Satoshi;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Kanazu, Masaki;
    • Mori, Masahide;
    • Nagata, Kenji
    Publication type:
    journal article